Percutaneous radiofrequency ablation of lung tumors: evaluation of the literature using evidence-based techniques.
AffiliationDepartment of Radiology, St Vincent's University Hospital, Dublin, Ireland.
MeSH*Catheter Ablation/statistics & numerical data
Databases as Topic
MetadataShow full item record
CitationJ Thorac Imaging. 2011 Feb;26(1):18-26.
JournalJournal of thoracic imaging
AbstractPURPOSE: The aim of this study was to evaluate the literature for articles assessing radiofrequency ablation (RFA) for pulmonary malignancy. MATERIALS AND METHODS: The "bottom-up" approach to evidence-based practice was applied by 2 reviewers to the retrieval and appraisal of original research articles published on pulmonary RFA between 2002 and 2009. Primary lung cancer and pulmonary metastases data were analyzed separately. The relationship between the percentage of local recurrence rate and lesion size, patient age, follow-up duration, and time to local recurrence was assessed using Spearman's rank correlation. Discrete time series were used to evaluate time trends. RESULTS: Secondary evidence yielded 1 review of 26 observational studies. Primary evidence yielded 46 studies that seemed suitable for detailed appraisal. A total of 2905 ablations were performed in 1584 patients. Eight studies evaluated primary lung cancers alone, 11 evaluated pulmonary metastases alone, 25 evaluated both, and 2 did not specify the histology. Results revealed trends toward increasing use of conscious sedation over general anesthesia, increasing use of multitined probes, decreasing size of nodule selection, and use of positron emission tomography/computed tomography as the optimal follow-up tool. Mean morbidity was 24.6%. The most prevalent side effects included pneumothorax (28.3%), pleural effusions (14.8%), and pain (14.1%). Procedure-related mortality ranged from 0 to 5.6, with an overall procedure-related mortality rate of 0.21%. There were 282 (12.2%) local recurrences occurring at a mean of 13 months. The mean overall survival rate was 59.4%, and the cancer-specific survival rate was 82.6%. CONCLUSIONS: This evidence-based practice review of pulmonary RFA shows it to be a promising treatment for pulmonary malignancy in carefully selected patient populations. Studies with higher levels of evidence, including case-control, prospective nonrandomized and randomized trials, that compare RFA with alternative contemporary local treatments are urgently needed.
- Extending indications for radiofrequency ablation of lung tumors through an intraoperative approach.
- Authors: Linden PA, Wee JO, Jaklitsch MT, Colson YL
- Issue date: 2008 Feb
- Factors contributing to cavitation after CT-guided percutaneous radiofrequency ablation for lung tumors.
- Authors: Okuma T, Matsuoka T, Yamamoto A, Oyama Y, Inoue K, Nakamura K, Inoue Y
- Issue date: 2007 Mar
- Percutaneous radiofrequency ablation of pulmonary metastases from colorectal carcinoma: prognostic determinants for survival.
- Authors: Yan TD, King J, Sjarif A, Glenn D, Steinke K, Morris DL
- Issue date: 2006 Nov
- Which patients will benefit from percutaneous radiofrequency ablation of colorectal liver metastases? Critically appraised topic.
- Authors: McGrane S, McSweeney SE, Maher MM
- Issue date: 2008 Jan-Feb
- Radiofrequency ablation of pulmonary malignant tumors in nonsurgical candidates.
- Authors: Herrera LJ, Fernando HC, Perry Y, Gooding WE, Buenaventura PO, Christie NA, Luketich JD
- Issue date: 2003 Apr